Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06179095
Other study ID # KirklareliED-4
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 1, 2024
Est. completion date February 28, 2026

Study information

Verified date June 2024
Source Kirklareli University
Contact Ayça SOLT KIRCA, Phd
Phone +905392684185
Email aycasolt@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was planned to determine whether the use of virtual reality glasses during intrauterine device insertion has an effect on the anxiety level of women.


Description:

Intrauterine device (IUD), which is one of the effective contraceptive methods in our country, is one of the known and frequently used methods. According to TDHS 2018 data, it was reported that 35% of women used IUD at some point in time, while the rate of women who were currently protected from pregnancy with IUD was 14% (TDHS, 2018). The fact that the rate of IUD use at any time is higher than the rate of current IUD users shows that the method is abandoned for various reasons (Kutlu & Kılıçaslan, 2014). However, although it is the most well-known method and used by one in three women in a period, the low rate of IUD use may be due to reasons such as the need to go to a health institution for application and controls, the feeling of embarrassment, discomfort and fear due to lack of information about the procedure, as well as known side effects (Kartal et al., 2013; Tan et al., 2022). However, in today's practice, no attempt is made to remove or reduce the discomfort of women, especially from vaginal examinations. It is known that virtual reality glasses are used in many areas. The most frequently used of these is the health sector. It can be used for educational purposes as well as for treatment and rehabilitation purposes. It has been stated that with virtual reality applications in treatment and rehabilitation processes, patient motivation will increase and patient fear and anxiety will decrease (Holden, 2005; Riener & Harders, 2012;Öztürk & Sondaş, 2020). In the light of the literature, it was determined that virtual reality goggles were not applied to reduce women's fear, anxiety and anxiety during IUD application. In this context, this study was planned to determine whether virtual reality goggles affect the anxiety level of women during IUD application.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date February 28, 2026
Est. primary completion date February 28, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - -Volunteering to participate in the research - Answering questionnaire and scale forms completely - Read and understand Turkish - 18 years of age or older - STAI score of 35 and above - Not being pregnant, - No complaints of acute pelvic pain, - No damage or leysone in the perineum that may cause pain during examination, - Not using a pharmacological agent or method with analgesic or anxiolytic effect 24 hours before the application, - No vaginismus problem, - Absence of a history of sexual abuse, - Not having any physical or mental problems that may prevent communication. Exclusion Criteria: - -Not volunteering to participate in the research, - Incomplete responses to questionnaires and scale forms - Not understanding Turkish, - Under 18 years of age - Do not score less than 35 points on the STAI, - Don't be pregnant, - Complaint of acute pelvic pain, - Any damage or leysone in the perineum that may cause pain during examination, - Having used a pharmacological agent or method with analgesic or anxiolytic effect 24 hours before the application, - Having a vaginismus problem, - Previous history of sexual abuse, - Having any physical or mental problem that prevents communication.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Virtual reality
Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI just before the intrauterine device insertion procedure, and again with STAI after the procedure.

Locations

Country Name City State
Turkey 1.Murat State Hospital Edirne

Sponsors (1)

Lead Sponsor Collaborator
Kirklareli University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Introductory Information Form The form consists of questions about socio-demographic and intrauterine device insertion between one to six months
Primary The State/Trait Anxiety Inventory (STAI) This inventory was developed by Spielberg in 1973 and each of the subscales ranges from 1 (not at all) to 4 (very much). The lowest and highest scores that can be obtained from each subscale are 20 and 80, respectively. Higher scores are associated with more anxiety. The alpha value of the scale varies between 0.86 and 0.92 . Öner et al. 1983, it was shown that the alpha value of the Turkish version of the STAI ranged between 0.83 and 0.87.27. between one to six months
Primary Visual Anolag Scale (VAS) It was developed by Price et al. (1983) to assess the severity of pain (Price et al. 1983). It is a line, usually 10 cm long, horizontal or vertical, starting with "No Pain" and ending with "Intolerable Pain". This line may be just a straight line, or it may be divided into equal intervals, or it may have description words placed on the line to describe pain. It is generally accepted that the vertical line is easier to understand. The patient indicates the intensity of his/her pain with a mark on this line where he/she deems appropriate. The distance between the beginning of no pain and this point is measured in "cm" and recorded. Values vary between 0 and 10 and higher values indicate increased pain. Turkish validity and reliability was performed by Eti Aslan (Eti Aslan, 2004). between one to six months
See also
  Status Clinical Trial Phase
Completed NCT03686085 - Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women. Phase 3
Recruiting NCT05550064 - Structured Contraceptive Counseling During Pregnancy N/A
Completed NCT03383432 - Intrauterine Device Insertion: a Step for High Satisfaction N/A
Completed NCT03600064 - Misoprostol for Cervical Ripening Before Copper Intrauterine Device Removal N/A
Completed NCT05556421 - Can Uterocervical Angle Predict the Displacement of Copper Intrauterine Devices (T-Cu 380A)
Completed NCT04045548 - Vaginal Dinoprostone Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System in Women With no Previous Vaginal Delivery Phase 4
Completed NCT03870711 - 10% Lidocaine Spray for Intrauterine Device Insertion Phase 4
Completed NCT02898831 - Cold Compress for Pain Associated With Intrauterine Device Insertion N/A